Fiala

Peptide library › Cancer & imaging

Balixafortide

Also known as POL6326

In clinical trialsCancer & imaging

Experimental CXCR4 blocker studied with chemotherapy for advanced breast cancer; its Phase 3 trial failed.

What people use it for

What Balixafortide does in the body

A ring-shaped peptide that blocks CXCR4, a receptor tumours use to spread and to hide in protective environments.

Strength of evidence

Limited: early trials looked promising, but the Phase 3 FORTRESS trial with eribulin showed no benefit.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

Investigational. Not approved by the FDA.

How it's taken

Route: Drip into a vein (in trials)

How long it lasts (half-life): Not well established in published data

Keep track of Balixafortide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Balixafortide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Cancer & imaging